Русский
Pharmacoeconomic aspects of the treatment of anemia in russian patients with chronic kidney disease
V.V. Ryazhenov, S.G. Gorokhova
1 Department of Pharmaceutical Technology and Pharmacology, Faculty of Pharmacy, First MSMU n.a. I.M. Sechenov, Moscow; 2 Department of Family Medicine of the Institute of Professional Education First MSMU n.a. I.M. Sechenov, Moscow; 3 Scientific Clinical Center of the JSC Russian Railways, Moscow
A clinical and economic evaluation of the effectiveness of drugs stimulating erythropoiesis in patients with anemia and chronic kidney disease was performed. Pharmacoeconomic benefits of III generation drug stimulating erythropoiesis, C.E.R.A., the use of which allows to reduce the financial costs of the health system associated with pharmacotherapy of nephrogenic anemia, are explained.
Keywords: budget impact analysis, nephrogenic anemia, Кeywords: pharmacoeconomic analysis, C.E.R.A., darbepoetin alfa, chronic kidney disease
About the Autors
Information about the authors:
Ryazhenov V.V. – PhD in Pharmaceutical Sciences, Associate Professor at the Department of Pharmaceutical Technology and Pharmacology, Faculty of Pharmacy, First MSMU n.a. I.M. Sechenov
E-mail: ryazhenov@mail.ru
Gorokhova S.G. – MD, Professor at the Department of Family Medicine of the Institute of Professional Education First MSMU n.a. I.M. Sechenov
Similar Articles
